Tevogen Bio to Host AI and Healthcare Economics Panels at J.P. Morgan Healthcare Conference
Curated by THEOUTPOST
On Fri, 27 Dec, 12:02 AM UTC
4 Sources
4 Sources
[1]
Tevogen Bio to Host Panel Discussions "AI In Biopharma: Next Frontier of Medical Innovation" and "Pioneering the Economics of Health
WARREN, N.J., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Time (PST): 2:00 PM - 2:30 PM - AI in Biopharma: Next Frontier of Medical Innovation Panelists: Dr. David Rhew - Global Chief Medical Officer and VP of Healthcare, Microsoft (Nasdaq: MSFT) Dr. Sean Tunis - Principal, Rubix Health Mittul Mehta - Chief Information Officer and Head of Tevogen.AI, Tevogen Bio 2:30 pm - 3:15 pm - Afternoon Coffee Break 3:15 PM - 4:00 PM - Pioneering the Economics of Health: Balancing Access and Outcomes Victor Sordillo - MD, Risk Advisory Services, Verita CSG, Inc; Member, Board of Directors, Tevogen Bio Peter Ehrhardt - Senior Partner at Simon-Kucher & Partners Dr. Poonam Alaigh - Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs; Former Commissioner, New Jersey Department of Health Dr. Sean Tunis - Principal, Rubix Health; Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health; Venture Mentor, Johns Hopkins Tech Ventures Dr. Ryan Saadi - Founder and CEO, Tevogen Bio 4:00 PM - 6:00 PM - Reception and Cocktails For inquiries regarding additional event details, please contact communications@tevogen.com. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
[2]
Tevogen Bio to Host Panel Discussions AI In Biopharma, Next Frontier of Medical Innovation and Pioneering the Economics of Health, Balancing Access and Outcomes During J.P. Morgan Healthcare Conference
- Chief Information Officer and Head of Tevogen.AI, Tevogen Bio Dr. Poonam Alaigh - Former Acting Under Secretary for Health, ; Former Commissioner, Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
[3]
Tevogen Bio to Host Panel Discussions AI In Biopharma: Next Frontier of Medical Innovation and Pioneering the Economics of Health: Balancing Access and Outcomes During J.P. Morgan Healthca By Investing.com
WARREN, N.J., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (Tevogen or Tevogen Bio Holdings Inc.) (Nasdaq: TVGN), will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. 3:15 PM " 4:00 PM " Pioneering the Economics of Health: Balancing Access and Outcomes Victor Sordillo " MD, Risk Advisory Services, Verita CSG, Inc; Member, Board of Directors, Tevogen Bio Peter Ehrhardt " Senior Partner at Simon-Kucher & Partners Dr. Poonam Alaigh " Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs; Former Commissioner, New Jersey Department of Health Dr. Sean Tunis - Principal, Rubix Health; Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health; Venture Mentor, Johns Hopkins Tech Ventures Dr. Ryan Saadi " Founder and CEO, Tevogen Bio 4:00 PM " 6:00 PM " Reception and Cocktails For inquiries regarding additional event details, please contact communications@tevogen.com. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
[4]
Tevogen Bio to Host Panel Discussions "AI In Biopharma: Next Frontier of Medical Innovation" and "Pioneering the Economics of Health: Balancing Access and Outcomes" During J.P. Morgan Healthcare Conference - Microsoft (NASDAQ:MSFT), Tevogen Bio Holdings (NASDAQ:TVGN)
The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.Pioneering the Economics of Health to examine the interdependencies of the healthcare ecosystem which are often overlooked when only considering a singular silo of it.AI In Biopharma to highlight how AI-driven technologies can revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster quicker innovation, and significantly reduce operating costs.Panelists to include David Rhew (Global Chief Medical Officer and VP of Healthcare, Microsoft), Sean Tunis (Principal, Rubix Health), Peter Ehrhardt (Senior Partner, Simon-Kucher), and Poonam Alaigh (Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs). WARREN, N.J., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") TVGN, will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Event Details Date: Monday, January 13, 2025 Location: Marines' Memorial Club & Hotel, 609 Sutter St., San Francisco, CA 94102 Time (PST): 2:00 PM - 2:30 PM - AI in Biopharma: Next Frontier of Medical Innovation Panelists: Dr. David Rhew - Global Chief Medical Officer and VP of Healthcare, Microsoft MSFT Dr. Sean Tunis - Principal, Rubix Health Mittul Mehta - Chief Information Officer and Head of Tevogen.AI, Tevogen Bio 2:30 pm - 3:15 pm - Afternoon Coffee Break 3:15 PM - 4:00 PM - Pioneering the Economics of Health: Balancing Access and Outcomes Victor Sordillo - MD, Risk Advisory Services, Verita CSG, Inc; Member, Board of Directors, Tevogen Bio Peter Ehrhardt - Senior Partner at Simon-Kucher & Partners Dr. Poonam Alaigh - Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs; Former Commissioner, New Jersey Department of Health Dr. Sean Tunis - Principal, Rubix Health; Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health; Venture Mentor, Johns Hopkins Tech Ventures Dr. Ryan Saadi - Founder and CEO, Tevogen Bio 4:00 PM - 6:00 PM - Reception and Cocktails For inquiries regarding additional event details, please contact communications@tevogen.com. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 Communications@Tevogen.com MSFTMicrosoft Corp$439.500.04%Overview Rating:Good62.5%Technicals Analysis1000100Financials Analysis400100WatchlistOverviewTVGNTevogen Bio Holdings Inc$1.03-3.73%TVGNWTevogen Bio Holdings Inc$0.05003.73%Market News and Data brought to you by Benzinga APIs
Share
Share
Copy Link
Tevogen Bio announces two panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference, focusing on AI in biopharma and the economics of healthcare, featuring industry experts from Microsoft, Rubix Health, and other organizations.
Tevogen Bio Announces AI and Healthcare Panels at J.P. Morgan Conference
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is set to host two significant panel discussions at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on January 13, 2025 1234. The event, known as the largest and most informative healthcare investment symposium in the industry, will feature discussions on artificial intelligence in biopharma and the economics of healthcare.
AI in Biopharma: Next Frontier of Medical Innovation
The first panel, scheduled from 2:00 PM to 2:30 PM PST, will focus on the role of AI in the biopharmaceutical industry 14. This discussion aims to highlight how AI-driven technologies can revolutionize various aspects of the healthcare sector, including:
- Accelerating drug discovery processes
- Enhancing patient accessibility
- Fostering quicker innovation
- Significantly reducing operating costs
The panel will feature notable speakers such as Dr. David Rhew, Global Chief Medical Officer and VP of Healthcare at Microsoft (Nasdaq: MSFT), Dr. Sean Tunis from Rubix Health, and Mittul Mehta, Chief Information Officer and Head of Tevogen.AI at Tevogen Bio 14.
Pioneering the Economics of Health: Balancing Access and Outcomes
Following a coffee break, a second panel from 3:15 PM to 4:00 PM PST will delve into the economics of healthcare 134. This discussion aims to examine the often-overlooked interdependencies within the healthcare ecosystem, moving beyond singular silos to consider the broader economic landscape.
Panelists for this session include:
- Victor Sordillo, MD of Risk Advisory Services at Verita CSG, Inc. and Tevogen Bio Board Member
- Peter Ehrhardt, Senior Partner at Simon-Kucher & Partners
- Dr. Poonam Alaigh, Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs
- Dr. Sean Tunis, Principal at Rubix Health and Senior Fellow at Tufts Center for Evaluation of Value and Risk in Health
- Dr. Ryan Saadi, Founder and CEO of Tevogen Bio 134
Tevogen Bio's Innovative Approach
Tevogen Bio, the host of these panels, is a clinical-stage specialty immunotherapy company focusing on developing off-the-shelf, genetically unmodified precision T cell therapies 1234. The company's approach targets infectious diseases, cancers, and neurological disorders, aiming to address significant unmet needs in large patient populations.
Tevogen's leadership emphasizes the importance of patient accessibility through advanced science and innovative business models. The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including patents related to artificial intelligence 1234.
Event Details and Significance
The panel discussions will take place at the Marines' Memorial Club & Hotel in San Francisco, with a reception and cocktails following from 4:00 PM to 6:00 PM 4. This event represents a significant opportunity for industry leaders, emerging companies, and investors to engage in discussions about the future of healthcare, particularly in the realms of AI application and economic sustainability.
As the healthcare industry continues to evolve, events like these play a crucial role in shaping the future of medical innovation and accessibility. The convergence of AI technology and healthcare economics at this conference underscores the growing importance of interdisciplinary approaches in addressing complex healthcare challenges.
Reference
[1]
Tevogen Bio Showcases AI-Driven Precision T Cell Therapy Development at AI x Bio Philly Event
Tevogen Bio's CIO presented the company's AI-driven technology for accelerating T cell therapy development at a prominent biotech event, highlighting the intersection of AI and biotechnology in Philadelphia.
2 Sources
2 Sources
Tevogen Bio Expands AI Collaboration with Microsoft to Accelerate Drug Development
Tevogen Bio announces an expanded partnership with Microsoft to leverage AI and cloud capabilities in drug discovery, aiming to revolutionize immunotherapy development and accelerate preclinical processes.
4 Sources
4 Sources
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances AI-Driven Immunotherapy
Tevogen Bio's CEO, Ryan Saadi, has been recognized on NJBIZ's 2025 Health Care Power List. The company, leveraging AI for immunotherapy drug discovery, also appointed a new Global Head of Government Affairs and Patient Access, supporting its commercialization strategy.
2 Sources
2 Sources
Tevogen Bio Advocates for Long COVID Patients in Congressional Meetings
Tevogen Bio's leadership met with U.S. Congress members to discuss Long COVID patient advocacy and showcase the company's innovative biotech model. The meetings highlighted Tevogen's achievements and potential impact on the biotech industry.
2 Sources
2 Sources
Tevogen Bio CEO Ryan Saadi Reaffirms Growth Strategy and Commitment to Precision T Cell Technology
Tevogen Bio's CEO Ryan Saadi expresses confidence in the company's growth strategy and reaffirms commitment to advancing precision T cell technology. The biotech firm aims to address large and underserved global health challenges.
2 Sources
2 Sources
Your one-stop AI hub
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
The Outpost
Keep in touch
© 2025 TheOutpost.AI All rights reserved